News articles about Incyte (NASDAQ:INCY) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Incyte earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.7287265835935 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s rankings:
- Incyte Is Worth $80 Even Without Epacadostat (seekingalpha.com)
- Cancer Anorexia-Cachexia Syndrome – Pipeline Review, H1 2018 Covers Key Players Aeterna Zentaris, Aphios, Incyte – Healthcare Journal (journalhealthcare.com)
- Incyte’s Revenue Trends in 4Q17 (finance.yahoo.com)
- Immunovaccine Announces Year-End 2017 Financial Results (markets.businessinsider.com)
- Incyte hikes CEO Hoppenot’s pay 36%—to $16M—despite its R&D setbacks (fiercepharma.com)
INCY has been the topic of a number of research analyst reports. Deutsche Bank initiated coverage on shares of Incyte in a report on Tuesday, December 12th. They issued a “hold” rating and a $106.00 price target on the stock. Oppenheimer reiterated a “hold” rating and issued a $110.00 price target (down previously from $120.00) on shares of Incyte in a report on Monday, January 22nd. Zacks Investment Research lowered shares of Incyte from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Credit Suisse Group set a $145.00 target price on shares of Incyte and gave the company a “buy” rating in a report on Wednesday, February 14th. Finally, Citigroup restated a “market perform” rating and set a $120.00 target price (down previously from $135.00) on shares of Incyte in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Incyte currently has an average rating of “Buy” and a consensus target price of $142.83.
Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm had revenue of $444.20 million for the quarter, compared to the consensus estimate of $435.23 million. During the same quarter in the previous year, the firm posted $0.05 EPS. The firm’s quarterly revenue was up 36.0% on a year-over-year basis. sell-side analysts predict that Incyte will post -0.26 earnings per share for the current year.
In related news, insider David W. Gryska sold 6,760 shares of Incyte stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the sale, the insider now owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Vijay K. Iyengar sold 5,000 shares of Incyte stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total transaction of $486,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,670 shares of company stock worth $1,489,181 in the last ninety days. 17.70% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Incyte (INCY) Stock Price” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3297645/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-incyte-incy-stock-price.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.